Resultado de búsqueda
3 de jul. de 2023 · The principal aim of filgrastim is to reduce the incidence of infection manifested by febrile neutropenia in patients receiving myelosuppressive chemotherapy. Thus, being alert to signs of infection would guide dosage and improve response outcomes in these patients.
Filgrastim is a form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy. Brand Names. Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio. Generic Name.
Indicated for long-term administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with severe...
Medical uses. Filgrastim is used to treat neutropenia; [14] acute myeloid leukemia; [14] nonmyeloid malignancies; [14] leukapheresis; [14] congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia; [14] and myelosuppressive doses of radiation. [14] [18]
Filgrastim injection products (Granix, Neupogen, Nivestym, Releuko, Zarxio) are used to decrease the chance of infection in people who have non myeloid cancer (cancer that does not involve the bone marrow) and are receiving chemotherapy medications that may decrease the number of neutrophils (a type of blood cell needed to fight infection).
Learn about NEUPOGEN® (filgrastim), a daily injectable granulocyte colony-stimulating factor (GCS-F) available in two administration options.
NEUPOGEN® is the Amgen Inc. trademark for filgrastim‚ which has been selected as the name for recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF). NEUPOGEN® is a 175 amino acid protein manufactured by recombinant DNA technology.1 NEUPOGEN® is produced by Escherichia coli (E coli) bacteria into which has been ...
